On April 3, 2017 a nationwide consumer class settlement was filed against drugmaker Mylan concerning the fraudulent overpricing of the widely distributed EpiPens® over the past decade.
The firm’s investigation shows that Mylan has increased the EpiPens® price by 500%, while all indicators demonstrate that actual prices of the medication should have stayed constant or even dropped. The result is that many people who needed this widely used medication had to go through extreme means to acquire the drug, or possibly were simply unable to obtain access to proper medication.
You may still be eligible to participate in the settlement, so please take a moment to review the following information. This case may be applicable to you if:
Please call or email us for more information about this case.